To treat growth failure due to inadequate secretion of endogenous growth hormone FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 1 To treat growth failure due to inadequate secretion of endogenous growth hormone drug. 1 FDA approval recorded, most recently Ngenla (somatrogon-ghla) on June 27, 2023.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Ngenla (somatrogon-ghla) | PFE | biologic | — |
Upcoming catalysts
No events in this view.
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| June 27, 2023 | Ngenla (somatrogon-ghla) | PFE | FDA approval | To treat growth failure due to inadequate secretion of endogenous growth hormone | Approved | FDA Novel Drug Approvals |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.
Questions
What To treat growth failure due to inadequate secretion of endogenous growth hormone drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.